Report
EUR 13.54 For Business Accounts Only

Thanks to a better fundamental star rating, CHRES.DBLE.-CRANE PHARM. sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to CHRES.DBLE.-CRANE PHARM. (CN), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date October 29, 2019, the closing price was CNY 12.65 and its expected value was estimated at CNY 12.67.
Underlying
China Resources Double-Crane Pharmaceutical (A)

Beijing Double-Crane Pharmaceutical is engaged in the process and manufacture of raw material medicine, injection, tablet, capsule, granule, and pharmaceutical machinery equipment; the sale of self-developed products, mechanical and electrical equipment; and the provision of development and transfer of technology and related services. Through its subsidiaries, Co. is also engaged in the manufacture and sale of building decoration materials and cleaning products; the import and export of pharmaceutical products and machinery equipment; investment management; the manufacture and sale of beverage and health food; the installation of electro-mechanical equipment; and the maintenance of pipeline.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch